Trending Topic

3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
9 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

Dedee Murrell, Dermatology Meeting News 2021: BELIEVE Phase 2 Study of Rilzabrutinib in Pemphigus

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 7th 2021

It was a pleasure to be able to speak with Prof. Dedee Murrell (St George Hospital, University of New South Wales, Sydney, Australia) about the BELIEVE Phase 2 (Part A) Study (NCT02704429) which investigated the oral BTK inhibitor, rilzabrutinib, in pemphigus.

Her abstract entitled ‘Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid Use and Improved Quality of Life in Patients With Chronic Relapsing Pemphigus: BELIEVE Phase II Study (Part A)’ was presented at the AAD VMX, 23-25 April 2021.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.  

Questions

  1. What is the rationale for the use of BTK inhibitors in pemphigus? (0:05)
  2. What were the aims, design and patient population of the BELIEVE study? (0:51)
  3. What were the efficacy and quality of life endpoints of the study and how well were these achieved? (2:10)
  4. What were the safety and tolerability findings of the study? (3:18)
  5. What future studies are planned? (4:14)

Disclosures: Prof. Dedee Murrell has acted and an investigator and advisor for Principia-Sanofi, ArgenX, Roche-Genentech and Eli Lilly. Prof. Murrell is also the co-inventor of the PDAI and ABQOL measures.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.

Filmed in coverage of the AAD VMX 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup